vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and BrightSpire Capital, Inc. (BRSP). Click either name above to swap in a different company.

BrightSpire Capital, Inc. is the larger business by last-quarter revenue ($83.2M vs $45.1M, roughly 1.8× Amarin Corp plc). BrightSpire Capital, Inc. runs the higher net margin — -17.3% vs -23.3%, a 6.0% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -0.4%). Over the past eight quarters, BrightSpire Capital, Inc.'s revenue compounded faster (-6.8% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Oakley Capital Investments, is a large British investment trust focused on investments in mid-market companies in the business services, consumer, education and technology sectors. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

AMRN vs BRSP — Head-to-Head

Bigger by revenue
BRSP
BRSP
1.8× larger
BRSP
$83.2M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+7.4% gap
AMRN
7.0%
-0.4%
BRSP
Higher net margin
BRSP
BRSP
6.0% more per $
BRSP
-17.3%
-23.3%
AMRN
Faster 2-yr revenue CAGR
BRSP
BRSP
Annualised
BRSP
-6.8%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
BRSP
BRSP
Revenue
$45.1M
$83.2M
Net Profit
$-10.5M
$-14.4M
Gross Margin
Operating Margin
35.5%
Net Margin
-23.3%
-17.3%
Revenue YoY
7.0%
-0.4%
Net Profit YoY
33.0%
27.3%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
BRSP
BRSP
Q1 26
$45.1M
Q4 25
$49.2M
$83.2M
Q3 25
$49.7M
$83.9M
Q2 25
$72.7M
$85.9M
Q1 25
$42.0M
$77.6M
Q4 24
$62.3M
$83.5M
Q3 24
$42.3M
$88.2M
Q2 24
$67.5M
$91.4M
Net Profit
AMRN
AMRN
BRSP
BRSP
Q1 26
$-10.5M
Q4 25
$-1.2M
$-14.4M
Q3 25
$-7.7M
$984.0K
Q2 25
$-14.1M
$-23.1M
Q1 25
$-15.7M
$5.3M
Q4 24
$-48.6M
$-19.7M
Q3 24
$-25.1M
$12.7M
Q2 24
$1.5M
$-67.9M
Gross Margin
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
BRSP
BRSP
Q1 26
35.5%
Q4 25
-12.9%
Q3 25
-22.4%
-1.7%
Q2 25
-22.0%
-54.5%
Q1 25
-39.9%
5.1%
Q4 24
-84.3%
-24.9%
Q3 24
-59.5%
13.2%
Q2 24
-0.8%
-74.9%
Net Margin
AMRN
AMRN
BRSP
BRSP
Q1 26
-23.3%
Q4 25
-2.5%
-17.3%
Q3 25
-15.6%
1.2%
Q2 25
-19.4%
-26.9%
Q1 25
-37.4%
6.9%
Q4 24
-78.0%
-23.7%
Q3 24
-59.4%
14.4%
Q2 24
2.3%
-74.2%
EPS (diluted)
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
$0.00
$-0.11
Q3 25
$-0.02
$0.00
Q2 25
$-0.03
$-0.19
Q1 25
$-0.04
$0.04
Q4 24
$-0.12
$-0.16
Q3 24
$-0.06
$0.09
Q2 24
$0.00
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
BRSP
BRSP
Cash + ST InvestmentsLiquidity on hand
$307.8M
$66.8M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$938.4M
Total Assets
$645.8M
$3.6B
Debt / EquityLower = less leverage
2.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
BRSP
BRSP
Q1 26
$307.8M
Q4 25
$302.6M
$66.8M
Q3 25
$286.6M
$113.4M
Q2 25
$298.7M
$154.3M
Q1 25
$281.8M
$200.9M
Q4 24
$294.2M
$302.2M
Q3 24
$305.7M
$263.8M
Q2 24
$306.7M
$203.3M
Total Debt
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
$2.5B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.3B
Q4 24
$2.5B
Q3 24
$2.6B
Q2 24
$2.5B
Stockholders' Equity
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
$459.3M
$938.4M
Q3 25
$458.9M
$976.4M
Q2 25
$464.9M
$994.4M
Q1 25
$473.7M
$1.0B
Q4 24
$486.2M
$1.0B
Q3 24
$531.4M
$1.1B
Q2 24
$551.9M
$1.1B
Total Assets
AMRN
AMRN
BRSP
BRSP
Q1 26
$645.8M
Q4 25
$670.8M
$3.6B
Q3 25
$659.8M
$3.3B
Q2 25
$670.1M
$3.4B
Q1 25
$655.7M
$3.6B
Q4 24
$685.3M
$3.7B
Q3 24
$750.6M
$3.8B
Q2 24
$799.9M
$3.8B
Debt / Equity
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
2.63×
Q3 25
2.22×
Q2 25
2.27×
Q1 25
2.27×
Q4 24
2.38×
Q3 24
2.36×
Q2 24
2.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
BRSP
BRSP
Operating Cash FlowLast quarter
$73.0M
Free Cash FlowOCF − Capex
$55.1M
FCF MarginFCF / Revenue
66.2%
Capex IntensityCapex / Revenue
21.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$102.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
$15.3M
$73.0M
Q3 25
$-12.7M
$29.9M
Q2 25
$16.6M
$17.4M
Q1 25
$-12.5M
$10.5M
Q4 24
$-13.3M
$103.4M
Q3 24
$-2.4M
$31.3M
Q2 24
$-2.7M
$22.9M
Free Cash Flow
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
$55.1M
Q3 25
$27.4M
Q2 25
$11.6M
Q1 25
$8.0M
Q4 24
$97.3M
Q3 24
$28.3M
Q2 24
$22.7M
FCF Margin
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
66.2%
Q3 25
32.7%
Q2 25
13.4%
Q1 25
10.3%
Q4 24
116.6%
Q3 24
32.1%
Q2 24
24.9%
Capex Intensity
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
21.6%
Q3 25
2.9%
Q2 25
6.8%
Q1 25
3.2%
Q4 24
7.3%
Q3 24
3.4%
Q2 24
0.1%
Cash Conversion
AMRN
AMRN
BRSP
BRSP
Q1 26
Q4 25
Q3 25
30.36×
Q2 25
Q1 25
1.97×
Q4 24
Q3 24
2.46×
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

BRSP
BRSP

Segment breakdown not available.

Related Comparisons